Delivery Order SPE2DE21D0007-SPE2D625F0NAW
- Not listed
- Ortho-Clinical Diagnostics, Inc., headquartered in Raritan, New Jersey, was awarded a delivery order valued at $1,910.02 on August 6, 2025, for Anti-A Bioclone 15x10ml medical diagnostic reagents. The contract, which will be completed by August 27, 2025, was issued without a set-aside designation, indicating open competition. The funding originates from the Medical Supply Chain within the Department of Defense, with the place of performance located in Raritan, New Jersey. This delivery order...
- Ortho-Clinical Diagnostics, Inc. was awarded a delivery order on August 6, 2025, by the Defense Medical Supply Chain to supply ANTI-A BioclOne 15x10mL, a diagnostic reagent product. The contract is valued at $1,109.97 under a fixed-price arrangement with economic price adjustment provisions, with an ultimate completion date of August 11, 2025. The work will be performed at the company's facility in Raritan, New Jersey. No set-aside designation was utilized for this award, indicating open...
- Ortho-Clinical Diagnostics, Inc. was awarded a delivery order contract on July 11, 2025, by the Medical Supply Chain division of the Department of Defense for the supply of Anti-A Bioclone 15x10ml reagents, valued at $1,156.61. The contract employs fixed-price pricing with economic price adjustment provisions and is scheduled for ultimate completion by August 1, 2025. The work will be performed at the company's facility in Raritan, New Jersey. No set-aside designation was used in this...
- The U.S. Defense Department's Medical Supply Chain awarded a delivery order valued at $1,109.97 to Ortho-Clinical Diagnostics, Inc. for Anti-A Bioclone 15x10ML on August 1, 2025, with an ultimate completion date of August 6, 2025. The contract utilizes fixed-price pricing with economic price adjustment and carries no set-aside designation, indicating open competition. Performance will occur at the contractor's facility in Raritan, New Jersey. Ortho-Clinical Diagnostics, Inc., a for-profit...
- Ortho-Clinical Diagnostics, Inc. was awarded a $1,156.61 fixed-price delivery order by the Defense Medical Supply Chain on July 14, 2025, for the supply of Anti-A Bioclone 15x10ml reagent products. The contract is scheduled for ultimate completion by August 4, 2025, and will be performed at the company's facility in Raritan, New Jersey. No small business set-aside designation was utilized for this award, indicating open competition among qualified vendors. This delivery order represents a...
- Ortho-Clinical Diagnostics, Inc. was awarded a delivery order valued at $1,871.28 for Anti-A Bioclone 15x10ml on July 21, 2025, with an ultimate completion date of July 24, 2025. The contract utilizes fixed-price pricing with economic price adjustment and was awarded without a set-aside designation, indicating open competition. The work will be performed in Raritan, New Jersey, and is funded by the Defense Health Agency's Medical Supply Chain, which supports critical medical diagnostic...
- Ortho-Clinical Diagnostics, Inc. has been awarded a delivery order contract by the Defense Medical Supply Chain with a ceiling value of $1,767.32 for Rght Anti-A B Bcln 10ml Btl Orth Bb—a specialized blood bank diagnostic reagent. The contract award is dated July 18, 2025, with an ultimate completion date of July 30, 2025, and will be performed at the company's facility in Raritan, New Jersey. This delivery order employs fixed-price contracting with economic price adjustment and was awarded...
- The U.S. government's Defense Logistics Agency Troop Support Medical awarded a $1,832.54 fixed price delivery order contract to Ortho-Clinical Diagnostics, Inc. for the purchase of 4564336504 ANTI-A BIOCLONE 15X10ML medical supplies. The contract has an ultimate completion date of May 10, 2024. Ortho-Clinical Diagnostics, Inc. is a for-profit medical equipment manufacturer that provides a range of diagnostic solutions to federal agencies, including the Department of Veterans Affairs and...
- Ortho-Clinical Diagnostics Inc. was awarded a $201,879.93 delivery order against the Critical Analyzers, Laboratory (FSS-66-III) schedule contract to provide various orthopedic-clinical diagnostics reagents to the Defense Health Agency. The delivery order has a completion date of September 30, 2024 and was awarded on October 1, 2021 under a firm fixed price contracting method. Performance will take place in Raritan, New Jersey. Ortho-Clinical Diagnostics Inc. is a medical equipment...
- This is a federal contract award to Ortho-Clinical Diagnostics, Inc., a for-profit medical equipment manufacturer, by the Medical Supply Chain division of the Defense agency. The contract is for the delivery of REAGENT ANTI-A B BIOCLONE 10ML BOTTLE OR, a medical diagnostic product. The contract is a Delivery Order with a Firm Fixed Price of $1,963.68 and an ultimate completion date of April 21, 2025. There is no set-aside designation for this contract. Ortho-Clinical Diagnostics, Inc. is a...
- SPE2DE21D0007Indefinite Delivery Contract
- SPE2DE21D0007-SPE2D625F0NAWDelivery Order
Ortho-Clinical Diagnostics, Inc. was awarded a delivery order contract on August 8, 2025, for the supply of Anti-A Bioclone 15x10ML reagents, with a ceiling value of $1,832.54. The contract is structured as a fixed-price delivery order with economic price adjustment provisions and is set to complete by August 29, 2025. This award was issued without a set-aside designation, indicating open competition. The place of performance is located in Raritan, New Jersey, which serves as the company's headquarters and primary manufacturing facility. The contract is funded by the Medical Supply Chain, a defense-oriented federal agency, and represents a continuation of Ortho-Clinical Diagnostics' ongoing support to federal healthcare entities. The company specializes in providing critical diagnostic solutions, including laboratory reagents and consumables, to defense and civilian federal healthcare agencies such as the Department of Veterans Affairs, Indian Health Service, and Defense Health Agency. This delivery order award likely represents a task order issued under one of the company's existing Indefinite Delivery Vehicle contracts or GSA Schedule agreements that provide the framework for supplying laboratory diagnostic products and services to federal medical facilities.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $1.8k | 8/8/25 |